Kalaivani Paramasivan

Kalaivani Paramasivan

Auto-generated profile, based on publicly available information

Kalaivani Paramasivan

Microbiology and Fermentation Technology Department CSIR‐Central Food Technological Research Institute Mysuru India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2020 in Nutrition Research Reviews
Verified
Journal Article
Open access
PDF file
IBIrina Borodina
Irina Borodina
LKLouise C. Kenny
Louise C. Kenny
CMCathal M. McCarthy
Cathal M. McCarthy
KPKalaivani Paramasivan
Kalaivani Paramasivan
EPEtheresia Pretorius
Etheresia Pretorius
DKDouglas Kell
Douglas Kell
Ergothioneine (ERG) is an unusual thio-histidine betaine amino acid that has potent antioxidant activities. It is synthesised by a variety of microbes, especially fungi (including in mushroom fruiting bodies) and actinobacteria, but is not synthesised by plants and animals who acquire it via the soil and their diet, respectively. Animals have evolved a highly selective transporter for it, known as solute carrier family 22, member 4 (SLC22A4) in humans, signifying its importance, and ERG may even have the status of a vitamin. ERG accumulates differentially in various tissues, according to their expression of SLC22A4, favouring those such as erythrocytes that may be subject to oxidative stress. Mushroom or ERG consumption seems to provide significant prevention against oxidative stress in a large variety of systems. ERG seems to have strong cytoprotective status, and its concentration is lowered in a number of chronic inflammatory diseases. It has been passed as safe by regulatory agencies, and may have value as a nutraceutical and antioxidant more generally.

20 April 2017 in Critical Reviews in Biotechnology
Verified
Journal Article
Closed access
KPKalaivani Paramasivan
Kalaivani Paramasivan
SMSarma Mutturi
Sarma Mutturi
Terpenes are natural products with a remarkable diversity in their chemical structures and they hold a significant market share commercially owing to their distinct applications. These potential molecules are usually derived from terrestrial plants, marine and microbial sources. In vitro production of terpenes using plant tissue culture and plant metabolic engineering, although receiving some success, the complexity in downstream processing because of the interference of phenolics and product commercialization due to regulations that are significant concerns. Industrial workhorses’ viz., Escherichia coli and Saccharomyces cerevisiae have become microorganisms to produce non-native terpenes in order to address critical issues such as demand-supply imbalance, sustainability and commercial viability. S. cerevisiae enjoys several advantages for synthesizing non-native terpenes with the most significant being the compatibility for expressing cytochrome P450 enzymes from plant origin. Moreover, achievement of high titers such as 40 g/l of amorphadiene, a sesquiterpene, boosts commercial interest and encourages the researchers to envisage both molecular and process strategies for developing yeast cell factories to produce these compounds. This review contains a brief consideration of existing strategies to engineer S. cerevisiae toward the synthesis of terpene molecules. Some of the common targets for synthesis of terpenes in S. cerevisiae are as follows: overexpression of tHMG1, ERG20, upc2-1 in case of all classes of terpenes; repression of ERG9 by replacement of the native promoter with a repressive methionine promoter in case of mono-, di- and sesquiterpenes; overexpression of BTS1 in case of di- and tetraterpenes. Site-directed mutagenesis such as Upc2p (G888A) in case of all classes of terpenes, ERG20p (K197G) in case of monoterpenes, HMG2p (K6R) in case of mono-, di- and sesquiterpenes could be some generic targets. Efforts are made to consolidate various studies (including patents) on this subject to understand the similarities, to identify novel strategies and to contemplate potential possibilities to build a robust yeast cell factory for terpene or terpenoid production. Emphasis is not restricted to metabolic engineering strategies pertaining to sterol and mevalonate pathway, but also other holistic approaches for elsewhere exploitation in the S. cerevisiae genome are discussed. This review also focuses on process considerations and challenges during the mass production of these potential compounds from the engineered strain for commercial exploitation.

6 September 2017 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
KPKalaivani Paramasivan
Kalaivani Paramasivan
SMSarma Mutturi
Sarma Mutturi

1 March 2021 in Yeast
Verified
Journal Article
Closed access
PDF file
KPKalaivani Paramasivan
Kalaivani Paramasivan
AAAneesha A
Aneesha A
NGNabarupa Gupta
Nabarupa Gupta
SMSarma Mutturi
Sarma Mutturi

1 August 2019 in Biochemical Engineering Journal
Verified
Journal Article
Closed access
KPKalaivani Paramasivan
Kalaivani Paramasivan
PHPunil Kumar Hn
Punil Kumar Hn
SMSarma Mutturi
Sarma Mutturi

24 July 2018 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
KPKalaivani Paramasivan
Kalaivani Paramasivan
KRKavya Rajagopal
Kavya Rajagopal
SMSarma Mutturi
Sarma Mutturi